Stereochemistry | ABSOLUTE |
Molecular Formula | C47H56N6O10S |
Molecular Weight | 897.047 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 5 / 5 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
[H][C@@]12C[C@]1(NC(=O)[C@]3([H])C[C@H](CN3C(=O)[C@H](CCCCCC=C2)NC(=O)OC4CCCC4)OC5=C6OC7=CC=CC=C7C6=NC(=N5)C8=CC=C(OC(C)C)C=C8)C(=O)NS(=O)(=O)C9(C)CC9
InChI
InChIKey=GZRNOYTVBWWFLJ-NTPALUMKSA-N
InChI=1S/C47H56N6O10S/c1-28(2)60-32-21-19-29(20-22-32)40-49-38-34-16-11-12-18-37(34)63-39(38)42(50-40)61-33-25-36-41(54)51-47(44(56)52-64(58,59)46(3)23-24-46)26-30(47)13-7-5-4-6-8-17-35(43(55)53(36)27-33)48-45(57)62-31-14-9-10-15-31/h7,11-13,16,18-22,28,30-31,33,35-36H,4-6,8-10,14-15,17,23-27H2,1-3H3,(H,48,57)(H,51,54)(H,52,56)/b13-7-/t30-,33-,35+,36+,47-/m1/s1
Furaprevir (also known as TG-2349), an NS3/4A protease inhibitor, discovered and developed by TaiGen for the treatment of chronic hepatitis C. Furaprevir blocks the protease enzyme that is essential in hepatitis C virus replication. In April 2019, TaiGen started the Phase III trial of the combination therapy Furaprevir - Yimitasvir for the treatment of chronic hepatitis C patients.
Originator
Approval Year
Patents
Sample Use Guides
TG-2349 (Furaprevir) is available as a Swedish orange capsule (size 0) for oral administration. Each capsule contains an equivalent of 100 mg of TG-2349 spray dried solid (SDD) and the following inactive ingredients: microcrystalline cellulose, croscarmellose sodium, sodium lauryl sulfate, magnesium stearate, and colloidal silicon oxide.
Route of Administration:
Oral